Your description
Location: Canada, British Columbia, Burnaby
Employees: 51-200
Founded date: 2005
Investors 1
| Date | Name | Website |
| 13.07.2025 | Foresite C... | foresiteca... |
Mentions in press and media 6
| Date | Title | Description |
| 04.12.2024 | Hedge Funds and Healthcare: A New Frontier in Investment Strategy | In the world of finance, the dance between risk and reward is a constant. Recently, a new partner has joined the fray: healthcare expertise. Major hedge funds are turning to doctors and scientists, seeking an edge in the volatile pharmaceut... |
| 03.12.2024 | NanoVation Therapeutics: Funding Round Led By Convergent Ventures Completed | NanoVation Therapeutics, a company developing innovative technologies to overcome barriers to nucleic acid delivery, announced the expansion of its Board of Directors and the close of a funding round led by Convergent Ventures. These two de... |
| 08.03.2024 | Arbutus to Participate in Two Upcoming Investor Conferences | - |
| 13.12.2021 | Arbutus Biopharma : to receive $40 million in an upfront payment, up to $245 million in development and commercialization milestone payments, double-digit tiered royalties and a $15 million equity inv... | Arbutus to receive $40 million in an upfront payment, up to $245 million in development and commercialization milestone payments, double-digit tiered royalties and a $15 million equity investment WARMINSTER, Pa. and JINAN, China, Dec. 13, 2... |
| 29.06.2021 | Antios Therapeutics and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection | Antios Therapeutics, Inc. and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination of Arbutus’ proprietary GalNAc delivered RNA... |
| 06.10.2017 | Roivant looks to quickly turn the page, starting with a Phase 3 win | A new hormonal therapy designed to treat uterine fibroids called relugolix has finished a Phase 3 study in Japan, and the results are positive. That’s welcome news for a SoftBank-backed company based in Basel, Switzerland called Roivant Sci... |